Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Diffuse Large B-cell Lymphoma
DRUG: Zanubrutinib plus Lenalidomide as Maintenance Therapy
EFS, EFS was defined as the time from treatment initiation to progression, relapse, new treatment, or death by any cause, whichever occurred first., 2 years
PFS, PFS was defined as the time from study entry until disease progression or death by any cause, 2 years|OS, OS was defined as the time from treatment initiation to death by any cause., 2 years
The investigators will evaluate safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with diffuse large B-cell lymphoma post complete remission and have completed planed courses of chemotherapy . Event-free survival (EFS), progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.